Literature DB >> 6221670

Reconstruction of the renal artery after unsuccessful percutaneous transluminal angioplasty in children.

P C Guzzetta, B M Potter, S Kapur, E J Ruley, J Randolph.   

Abstract

The use of percutaneous transluminal angioplasty as the primary treatment of renovascular stenosis in adults has recently been described. Previously, only three children have been reported to have undergone transluminal angioplasty for stenosis of the renal artery and hypertension. At our hospital, transluminal angioplasty was attempted in four children with renal artery stenosis; one attempt was successful and three were unsuccessful. The three patients who required surgical repair of the renal artery after unsuccessful transluminal angioplasty have been described in detail. The histopathology of the stenotic vessels is also discussed. Based on the analysis of the three children, certain criteria have been derived to select pediatric patients with renovascular hypertension either for attempted transluminal angioplasty or for primary surgical revascularization.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6221670     DOI: 10.1016/0002-9610(83)90114-9

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Percutaneous transluminal renal angioplasty in neurofibromatosis.

Authors:  E Fossali; M Minoja; R Intermite; C Spreafico; E Casalini; F Sereni
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

Review 2.  Treatment of severe renal artery stenosis by percutaneous transluminal renal angioplasty and stent implantation: review of the pediatric experience: apropos of two cases.

Authors:  Kai König; Jutta Gellermann; Uwe Querfeld; Martin B E Schneider
Journal:  Pediatr Nephrol       Date:  2006-03-07       Impact factor: 3.714

3.  Percutaneous transluminal angioplasty for renovascular hypertension in children.

Authors:  R L Chevalier; C J Tegtmeyer; R A Gomez
Journal:  Pediatr Nephrol       Date:  1987-01       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.